Shariat - Figure 58
Conclusions
FIG. 58: What constitutes good outcomes in patients with T1 bladder cancer has been debated for >30 years. Risk stratification of aggressive versus less aggressive T1 disease remains to be tested and evaluated, although it is a dynamic field of research. More research is needed in cancer biology, since it is the primary mediator of mortality. Next-generation sequencing and integrated multiplatform analyses will better inform us about the biological potential of the cells, facilitating personalized therapeutic approaches and becoming an integral part of tumor boards. We will also determine the right therapy for the right patient based on that molecular information. Some of the targeted therapies are becoming available for the management of NMI bladder cancer with focus on the T1 high-grade cancers, displacing, replacing, or enhancing BCG therapy. In this setting, skilled surgery and understanding of the biology will be combined to inform our clinical practice.
